• Species Reactivity

  Human

• Specificity

  Detects human MIS/AMH in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant rat MIS/AMH is observed.

• Source

  Monoclonal Mouse IgG    ₁ Clone # 805531

• Purification

  Protein A or G purified from hybridoma culture supernatant

• Immunogen

  Mouse myeloma cell line NS0-derived recombinant human MIS/AMH    
  Leu19-Gln450 (predicted)    
  Accession # P03971

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

• Label

  Unconjugated

Applications

• 
  

  Recommended    
  Concentration

  Sample

• Immunocytochemistry

  8-25 µg/mL

  See below

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Data Examples

Preparation and Storage

• Reconstitution

  Sterile PBS to a final concentration of 0.5 mg/mL.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: MIS/AMH

Müllerian inhibiting substance (MIS), also named anti-Müllerian hormone (AMH), is a tissue-specific TGF-beta superfamily growth factor. Its expression is restricted to the Sertoli cells of fetal and postnatal testis, and to the granulosa cells of postnatal ovary (1). The human MIS gene encodes a 553 amino acid residue (aa) prepropeptide containing a signal a sequence (1-24), a pro-region (25-455), and the carboxyl-terminal bioactive protein (446-553) (2-4). MIS is synthesized and secreted as a disulfide-linked homodimeric pro-protein. Proteolytic cleavage is required to generate the N-terminal pro-region and the C-terminal bioactive protein, which remain associated in a non-covalent complex. Recombinant C-terminal MIS has been shown to be bioactive. However, the complex with the N-terminal pro-region showed enhanced activity (3, 5). The C-terminal region contains the seven canonical cysteine residues found in TGF-beta superfamily members. These cysteine residues are involved in inter- and intra-molecular disulfide bonds, which forms the cysteine knot structure. Human and mouse MIS share 73% and 90% aa sequence identity in their pro-region and C-terminal region, respectively. MIS induces Mullerian duct (female reproductive tract) regression during sexual differentiation in the male embryo (6). Postnatally, MIS has been shown to regulate gonadal functions (1). MIS inhibits Leydig cell proliferation and is a regulator of the initial and cyclic recruitment of ovarian follicles. MIS has also been found to have anti-proliferative effects on breast, ovarian and prostate tumor cells (7-9). Like other TGF-beta superfamily members, MIS signals via a heteromeric receptor complex consisting of a type I and a type II receptor serine/threonine kinase. Depending on the cell context, different type I receptors (including Act RIA/ALK2, BMP RIA/ALK3, and BMP RIB/ALK6) that are shared by other TGF-beta superfamily members, have been implicated in MIS signaling (10-12). In contrast, the type II MIS receptor (MIS RII) is unique and does not bind other TGF-beta superfamily members. Upon ligand binding, MIS RII recruits the non‑ligand binding type I receptor into the complex, resulting in phosphorylation the BMP-like signaling pathway effector proteins Smad1, Smad5, and Smad 8 (10-12).

• References:

1. Teixeira, et al. (2001) Endocrine Rev. 22:657.

2. Pepinsky, R.et al. (1988) J. Biol. Chem. 263:18961.

3. Wilson, C.A. et al. (1993) Mol. Endocrinol. 7:247.

4. Kurian, M.S. et al. (1995) Clin. Cancer Res. 1:343.

5. Nachtigal, J.S. and H.A. Ingraham (1996) Proc. Natl. Acad. Sci. USA 93:7711.

6. MacLaughlin, D.T. et al. (1991) Methods Enzymol. 35:358.

7. Laurich, V.M. et al. (2002) Endocrinology 143:3351.

8. McGee, E.A. et al. (2001) Biol. Reprod. 64:293.

9. Segev, D.L. et al. (2002) Proc. Natl. Acad. Sci. USA 99:239.

10. Josso, N and N. diClemente (2003) Trends Endo. Met. 14:91.

11. Clarke, T.R. et al. (2001) Mol. Endocrinol. 15:946.

12. Visser, J.A. (2003) Mol. Cell. Endocrinol. 211:65.

• Long Name:

  Mullerian-inhibiting Substance/Anti-Mullerian Hormone

• Entrez Gene IDs:

  268 (Human); 11705 (Mouse)

• Alternate Names:

  AMH; MIF; MIS; Muellerian hormone; muellerian-inhibiting factor; muellerian-inhibiting substance; Mullerian hormone; Mullerian inhibiting factor; Mullerian inhibiting substance